The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
Open accessAbstract
BACKGROUND: In patients with coronary heart disease and a broad range of cholesterol levels, cholesterol-lowering therapy reduces the risk of coronary events, but the effects on mortality from coronary heart disease and overall mortality have remained uncertain. METHODS: In a double-blind, randomized trial, we compared the effects of pravastatin (40 mg daily) with those of a placebo over a mean follow-up period of 6.1 years in 9014 patients who were 31 to 75 years of age. The patients had a history of myocardial infarction or hospitalization for unstable angina and initial plasma total cholesterol levels of 155 to 271 mg per deciliter. Both groups received advice on following a cholesterol-lowering diet. The primary study outcome was mortality from coronary heart disease. RESULTS: Death from coronary heart disease occurred in 8.3 percent of the patients in the placebo group and 6.4 percent of those in the pravastatin group, a relative reduction in risk of 24 percent (95 percent confidence interval, 12 to 35 percent; P<0.001). Overall mortality was 14.1 percent in the placebo group and 11.0 percent in the pravastatin group (relative reduction in risk, 22 percent; 95 percent confidence interval, 13 to 31 percent; P<0.001). The incidence of all cardiovascular outcomes was consistently lower among patients assigned to receive pravastatin; these outcomes included myocardial infarction (reduction in risk, 29 percent; P<0.001), death from coronary heart disease or nonfatal myocardial infarction (a 24 percent reduction in risk, P<0.001), stroke (a 19 percent reduction in risk, P=0.048), and coronary revascularization (a 20 percent reduction in risk, P<0.001). The effects of treatment were similar for all predefined subgroups. There were no clinically significant adverse effects of treatment with pravastatin. CONCLUSIONS: Pravastatin therapy reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A large body of evidence indicates that statin-based strategies convey similar LDL-C lowering and relative cardiovascular risk reduction in patients with and those without T2DM.102–112”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [103]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Data from RCTs and meta-analyses indicate that routine early use of high-intensity statin therapy is associated with rapid and sustained clinical benefits [438-442].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [442]
Experimental — accuracy not yet measuredIn the citing paper
“Although healthy lifestyle habits remain a cornerstone of T2DM management, trial data have confirmed the additional benefits of statin therapy in the primary and secondary prevention of CAD.13,102–112”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [103]
In the citing paper
“Pooling of results from RCTs suggested that cholesterol lowering with statin treatment reduced incident HF by 9-45% in patients with CAD.22,180”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [22]
In the citing paper
“Pooling of results from RCTs suggested that cholesterol lowering with statin treatment reduced incident HF by 9-45% in patients with CAD. 368,369”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [369]
In the citing paper
“Pooling of results from RCTs suggested that cholesterol lowering with statin treatment reduced incident HF by 9e45% in patients with CAD.368,369”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [369]
In the citing paper
“It was demonstrated in the REACH registry, a registry study on patients with ASCVD or overlapping risks factors for ASCVD, that approximately 16% registered cases are complicated with two or more ASCVD757).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [757]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Statistical Methods for Survival Data Analysis.
Lachenbruch, P. A., & Lee, E. T. (1993) · Journal of the American Statistical Association · doi:10.2307/2290742 · Cited by 2,851
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Muldoon, M. F., Manuck, S. B., & Matthews, K. A. (1990) · BMJ · doi:10.1136/bmj.301.6747.309 · Cited by 960
EUROASPIRE Study Group (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015136 · Cited by 665
Chen, Z., Peto, R., Collins, R., MacMahon, S. W., Lu, J., & Li, W. (1991) · BMJ · doi:10.1136/bmj.303.6797.276 · Cited by 537
Research works printed but not linked: 4
- Peto R, 1985, Circulation, 72, 451
- Keech A, 1992, Postgrad Med J, 68, 870
- 1994, Lancet, 344, 1383
- Keech A, 1998, Atherosclerosis, 136, S31
Cited by
Sorted by citations
Items 901–1,000 of 1,037
Nosaka, K., Miyoshi, T., Iwamoto, M., Kajiya, M., Okawa, K., Tsukuda, S., Yokohama, F., Sogo, M., Nishibe, T., Matsuo, N., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.105 · Cited by 88
Vijayakumar, M., Vasudevan, D. M., Sundaram, K. R., Krishnan, S., Vaidyanathan, K., Nandakumar, S., Chandrasekhar, R., & Mathew, N. (2016) · Indian Heart Journal · doi:10.1016/j.ihj.2015.10.384 · Cited by 88
Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?
Balakumar, P., Kathuria, S., Taneja, G., Kalra, S., & Mahadevan, N. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.09.014 · Cited by 88
Hall, R. N. (2012) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2012.09.013 · Cited by 88
Pharmacologic Prevention of Microvascular and Macrovascular Complications in Diabetes Mellitus
Tandon, N., Ali, M. K., & Narayan, K. M. V. (2012) · American Journal of Cardiovascular Drugs · doi:10.2165/11594650-000000000-00000 · Cited by 88
Antioxidants, statins, and atherosclerosis
Gotto, A. M. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00082-2 · Cited by 88
Otvos, J. D., SHALAUROVA, I. Y., Freedman, D. S., & Rosenson, R. S. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00544-5 · Cited by 88
Koren‐Morag, N. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.9.993 · Cited by 88
International Society of Hypertension (ISH)
International Society of Hypertension Writing Group (2003) · Journal of Hypertension · doi:10.1097/00004872-200304000-00002 · Cited by 88
Blazing, M. A., de Lemos, J. A., Dyke, C. K., Califf, R. M., Bilheimer, D. W., & Braunwald, E. (2001) · American Heart Journal · doi:10.1067/mhj.2001.116959 · Cited by 88
Rahman, M. S., & Woollard, K. J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-57613-8_7 · Cited by 87
Cho, K. H., Jeong, M. H., Ahn, Y., Kim, Y. J., Chae, S. C., Hong, T. J., Seong, I. W., Chae, J. K., Kim, C. J., Cho, M., et al. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.06.009 · Cited by 87
Effect of pravastatin on the development of diabetes and adiponectin production
Takagi, T., Matsuda, M., Abe, M., Kobayashi, H., Fukuhara, A., Komuro, R., Kihara, S., CASLAKE, M. J., McMahon, A. D., Shepherd, J., et al. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.02.013 · Cited by 87
Relative Effects of Statin Therapy on Stroke and Cardiovascular Events in Men and Women
Goldstein, L. B., Amarenco, P., LaMonte, M. P., Gilbert, S. A., Messig, M., Callahan, A., Hennerici, M. G., Sillesen, H. H., & Welch, K. M. A. (2008) · Stroke · doi:10.1161/strokeaha.107.513747 · Cited by 87
Ganse, E. H. V., Laforest, L., Alemao, E., Davies, G., Gutkin, S. W., & Yin, D. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x59139 · Cited by 87
Pretreatment with statins enhances myocardial protection during coronary revascularization
Lazar, H. L., Bao, Y., Zhang, Y., & Bernard, S. A. (2003) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1067/mtc.2003.177 · Cited by 87
Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study
Tonkin, A. M., Colquhoun, D., Emberson, J., Hague, W. E., KEECH, A. C., Lane, G., MacMahon, S. W., Simes, R. J., Thompson, P. L., White, H. D., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03257-8 · Cited by 87
Stein, D. T., Devaraj, S., Balis, D. S., ADAMS-HUET, B. A., & Jialal, I. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/hq1201.100259 · Cited by 87
Screening for early detection of cardiovascular disease in asymptomatic individuals
Cohn, J. N., Hoke, L., Whitwam, W., Sommers, P. A., Taylor, A. L., Duprez, D. A., Roessler, R., & Florea, N. D. (2003) · American Heart Journal · doi:10.1016/s0002-8703(03)00499-x · Cited by 87
Wolfram, R. M., Brewer, H. B., Xue, Z., Satler, L. F., Pichard, A. D., Kent, K. M., & Waksman, R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.04.006 · Cited by 86
Toi, T., Taguchi, I., Yoneda, S., Kageyama, M., Kikuchi, A., Tokura, M., Kanaya, T., Abe, S., Matsuda, R., & Kaneko, N. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-1051 · Cited by 86
Efficacy and safety of rosuvastatin in treatment of dyslipidemia
McKenney, J. M. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.10.1033 · Cited by 86
Consensus statement on management of dyslipidemia in Indian subjects
Chandra, K. S., Bansal, M., Nair, T., Iyengar, S. S., Gupta, R., Manchanda, S. C., Mohanan, P. P., Rao, V. D., Manjunath, C. N., Sawhney, J. P. S., et al. (2014) · Indian Heart Journal · doi:10.1016/j.ihj.2014.12.001 · Cited by 86
Evidences of the cardioprotective potential of fruits: The case of cranberries
Ruel, G., & Couillard, C. (2007) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200600286 · Cited by 86
Modulatory effects of HMG‐CoA reductase inhibitors in diabetic microangiopathy
Danesh, F. R., & Kanwar, Y. S. (2004) · The FASEB Journal · doi:10.1096/fj.03-0839rev · Cited by 86
Saltissi, D., Morgan, C., Rigby, R., & Westhuyzen, J. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.30547 · Cited by 86
Dyslipidemia and Cardiovascular Disease in Women
Cífková, R., & Krajčoviechová, A. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0609-5 · Cited by 86
Depression and cardiovascular morbidity and mortality: cause or consequence?
Stewart, R. (2003) · European Heart Journal · doi:10.1016/j.ehj.2003.08.017 · Cited by 86
Bozovich, M., Rubino, C. M., & Edmunds, J. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.17.1375.34895 · Cited by 86
Pharmacogenomics of cholesterol-lowering therapy
Schmitz, G., & Langmann, T. (2005) · Vascular Pharmacology · doi:10.1016/j.vph.2005.07.012 · Cited by 86
Hay, J. W., Yu, W., & Ashraf, T. (1999) · PharmacoEconomics · doi:10.2165/00019053-199915010-00004 · Cited by 86
Athyros, V. G., Papageorgiou, A. A., Symeonidis, A. N., Didangelos, T. P., Pehlivanidis, A. N., Bouloukos, V. I., & Mikhailidis, D. P. (2003) · Angiology · doi:10.1177/000331970305400607 · Cited by 85
Donnelly, L. A., Doney, A. S. F., Dannfald, J., Whitley, A. L., Lang, C. C., Morris, A. D., Donnan, P. T., & Palmer, C. N. A. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283106071 · Cited by 85
Antoniou, G. A., Hajibandeh, S., Hajibandeh, S., Vallabhaneni, S. R., Brennan, J. A., & Torella, F. (2014) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2014.10.021 · Cited by 85
Stojaković, T., Putz‐Bankuti, C., Fauler, G., Scharnagl, H., Wagner, M., Stadlbauer, V., Gurakuqi, G. C., Stauber, R. E., März, W., & Trauner, M. (2007) · Hepatology · doi:10.1002/hep.21741 · Cited by 85
Determinants of F2-isoprostane biosynthesis and inhibition in man
Davì, G., Falco, A., & Patrono, C. (2003) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2003.10.001 · Cited by 85
Antiinflammatory and Immunomodulatory Properties of Statins
Shovman, O., Levy, Y. M., Gilburd, B., & Shoenfeld, Y. (2002) · Immunologic Research · doi:10.1385/ir:25:3:271 · Cited by 85
Stewart, R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.20.3144 · Cited by 85
Grover, S. A., Coupal, L., Zowall, H., Alexander, C. M., Weiss, T. W., & Gomes, D. R. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.1.45 · Cited by 85
Crouse, J. R., Grobbee, D. E., O’Leary, D. H., Bots, M. L., Evans, G. W., Palmer, M. K., Riley, W. A., & Raichlen, J. S. (2004) · Cardiovascular Drugs and Therapy · doi:10.1023/b:card.0000033645.55138.3d · Cited by 85
Fonarow, G. C., & Gawlinski, A. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00933-9 · Cited by 85
Effects of Statins on Renal Function
Agarwal, R. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.11.1381 · Cited by 84
Chuengsamarn, S., Rattanamongkolgul, S., Suwanwalaikorn, S., Wattanasirichaigoon, S., & Kaufman, L. (2010) · Bone · doi:10.1016/j.bone.2009.12.023 · Cited by 84
Long‐term adherence to statin treatment in diabetes
Donnelly, L. A., Doney, A. S. F., Morris, A. D., Palmer, C. N. A., & Donnan, P. T. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02476.x · Cited by 84
Evidence That Value-Based Insurance Can Be Effective
Chernew, M. E., Juster, I. A., Shah, M. R., Wegh, A., Rosenberg, S. N., Rosen, A. B., Sokol, M. C., Yu-Isenberg, K. S., & Fendrick, A. M. (2010) · Health Affairs · doi:10.1377/hlthaff.2009.0119 · Cited by 84
Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor
Jeu, L., & Cheng, J. W. M. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80281-3 · Cited by 84
High-Density Lipoprotein Cholesterol and Coronary Heart Disease
Young, C. E., Karas, R. H., & Kuvin, J. T. (2004) · Cardiology in Review · doi:10.1097/01.crd.0000097140.29929.8a · Cited by 84
Safety of High-Dose Atorvastatin Therapy
Waters, D. D. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.028 · Cited by 84
Simes, R. J. (2002) · European Heart Journal · doi:10.1053/euhj.2001.2775 · Cited by 84
Maki, K. C., Bays, H. E., & Dicklin, M. R. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.04.003 · Cited by 83
Wu, H.-F., Hristeva, N., Chang, J. H., Liang, X., Li, R., Frassetto, L. A., & Benet, L. Z. (2017) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2017.03.027 · Cited by 83
Micallef, M. A., & Garg, M. L. (2009) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2009.06.009 · Cited by 83
McGowan, M. P. (2004) · Circulation · doi:10.1161/01.cir.0000145118.55201.15 · Cited by 83
The Impact of Medicare Part D on Hospitalization Rates
Afendulis, C. C., He, Y., Zaslavsky, A. M., & Chernew, M. E. (2011) · Health Services Research · doi:10.1111/j.1475-6773.2011.01244.x · Cited by 83
Peripheral arterial disease and cognitive function
Rafnsson, S. B., Deary, I. J., & Fowkes, F. G. R. (2009) · Vascular Medicine · doi:10.1177/1358863x08095027 · Cited by 83
Persistent psychological distress and mortality in patients with stable coronary artery disease
Stewart, R., Colquhoun, D. M., Marschner, S. L., Kirby, A. C., Simes, J. R., Nestel, P. J., Glozier, N., O'Neil, A. E., Oldenburg, B. F., White, H. D., et al. (2017) · Heart · doi:10.1136/heartjnl-2016-311097 · Cited by 83
Cholesterol Absorption Inhibitors for the Treatment of Hypercholesterolaemia
Sudhop, T., & von Bergmann, K. (2002) · Drugs · doi:10.2165/00003495-200262160-00002 · Cited by 83
Aronow, H. D., Novaro, G. M., Lauer, M. S., Brennan, D. M., Lincoff, A. M., Topol, E. J., Kereiakes, D. J., & Nissen, S. E. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.21.2576 · Cited by 83
van de Ree, M. A. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00379-0 · Cited by 83
Should Angiotensin II Receptor Blockers and Statins Be Combined?
Nickenig, G. (2004) · Circulation · doi:10.1161/01.cir.0000139857.85424.45 · Cited by 83
Statins and stroke: evidence for cholesterol-independent effects
Napoli, P. D. (2002) · European Heart Journal · doi:10.1053/euhj.2002.3236 · Cited by 83
Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia
Bilz, S., Wagner, S., Schmitz, M., Bedynek, A., Keller, U. B., & Demant, T. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m300309-jlr200 · Cited by 83
The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk
Corsini, A. (2003) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1026132412074 · Cited by 82
The Complex Interplay Between Cholesterol and Prostate Malignancy
Solomon, K. R., & Freeman, M. R. (2011) · Urologic Clinics of North America · doi:10.1016/j.ucl.2011.04.001 · Cited by 82
Heart disease in diabetic patients
Blendea, M. C., McFarlane, S. I., Isenović, E. R., GICK, G. G., & Sowers, J. R. (2003) · Current Diabetes Reports · doi:10.1007/s11892-003-0068-z · Cited by 82
Kopjar, B., Sales, A. E., Piñeros, S. L., Sun, H., Li, Y.-F., & Hedeen, A. N. (2003) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.07.008 · Cited by 82
Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance
Haffner, S. M. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02634-6 · Cited by 82
Soedamah‐Muthu, S. S. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(02)00428-8 · Cited by 82
Poli, A. (2007) · Drugs · doi:10.2165/00003495-200767001-00002 · Cited by 81
Medical Lipid-Regulating Therapy
Evans, M., Roberts, A. W., Davies, S., & Rees, A. (2004) · Drugs · doi:10.2165/00003495-200464110-00003 · Cited by 81
Prevalence and Phenotypic Distribution of Dyslipidemia in Type 1 Diabetes Mellitus
Pérez, A., Wägner, A. M., Carreras, G., Giménez‐Pérez, G., Sánchez‐Quesada, J. L., Rigla, M., Gómez-Gerique, J. A., Pou, J. M., & de Leiva, A. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.18.2756 · Cited by 81
Ishikawa, M., Okajima, F., Inoue, N., Motomura, K., Kato, T., Takahashi, A., Oikawa, S., Yamada, N., & Shimano, H. (2006) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.13.329 · Cited by 81
Saad, A. F., Kechichian, T. B., Yin, H., Sbrana, E., Longo, M., Wen, M., Tamayo, E. H., Hankins, G. D. V., Saade, G. R., & Costantine, M. M. (2013) · Reproductive Sciences · doi:10.1177/1933719113492207 · Cited by 81
Cardiovascular Disease and Dyslipidemia in Women
Welty, F. K. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.4.514 · Cited by 81
DIABETES MELLITUS AND CORONARY HEART DISEASE
Wilson, P. W. F. (2001) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70219-x · Cited by 81
Pignone, M. P., Phillips, C. J., Atkins, D., Teutsch, S. M., Mulrow, C. D., & Lohr, K. N. (2001) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(01)00255-0 · Cited by 81
Reducing Residual Risk for Patients on Statin Therapy: The Potential Role of Combination Therapy
Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.002 · Cited by 81
Wang, N., Woodward, M., Huffman, M. D., & Rodgers, A. (2022) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.121.008552 · Cited by 80
Chromatography–mass spectrometry methods for the quantitation of statins in biological samples
Nirogi, R. V. S., Mudigonda, K., & Kandikere, V. N. (2007) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2007.02.008 · Cited by 80
Ziff, O. J., Banerjee, G., Ambler, G., & Werring, D. J. (2018) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-318483 · Cited by 80
Grundy, S. M. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01931-2 · Cited by 80
Suppressive Effects of Statins on Acute Promyelocytic Leukemia Cells
Sassano, A., Katsoulidis, E., Antico, G., Altman, J. K., Redig, A. J., Minucci, S., Tallman, M. S., & Platanias, L. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3686 · Cited by 80
Managing the risk of atherosclerosis: the role of high-density lipoprotein
Libby, P. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02145-2 · Cited by 80
The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk.
Ginsberg, H. N., & Stalenhoef, A. F. H. (2003) · Journal of Cardiovascular Risk · doi:10.1097/00043798-200304000-00007 · Cited by 80
Velasco, J. A., Cosín, J., Maroto, J. M. D., Muñiz, J., Casasnovas, J. A., Plaza, I., & Abadal, L. T. (2000) · Revista Española de Cardiología · doi:10.1016/s0300-8932(00)75211-0 · Cited by 80
Fellström, B., Zannad, F. M., Schmieder, R. E., Holdaas, H., Jardine, A. G., Rose, H., Wilpshaar, W., & the AURORA Study Group (2005) · Current Controlled Trials in Cardiovascular Medicine · doi:10.1186/1468-6708-6-9 · Cited by 80
Self-citationPreventing Cardiovascular Disease in the 21st Century
Daviglus, M. L., Lloyd‐Jones, D. M., & Pirzada, A. (2006) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200606020-00003 · Cited by 79
Efficacy of Rosuvastatin (5 mg and 10 mg) Twice a Week in Patients Intolerant to Daily Statins
Gadarla, M., Kearns, A. K., & Thompson, P. D. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.061 · Cited by 79
Matsuzawa, Y., Kita, T., Mabuchi, H., Matsuzaki, M., Nakaya, N., Oikawa, S., Saitō, Y., Sasaki, J., Shimamoto, K., Itakura, H., et al. (2003) · Circulation Journal · doi:10.1253/circj.67.287 · Cited by 79
Self-citationCarlquist, J. F., Muhlestein, J. B., Horne, B. D., Hart, N. I., Bair, T. L., Molhuizen, H. O. F., & Anderson, J. L. (2003) · American Heart Journal · doi:10.1016/s0002-8703(03)00501-5 · Cited by 79
van Heek, M., Austin, T. M., Farley, C., Cook, J. A., Tetzloff, G. G., & Davis, H. R. (2001) · Diabetes · doi:10.2337/diabetes.50.6.1330 · Cited by 79
Wolffenbuttel, B. H. R., Franken, A. A. M., Vincent, H. H., & THE DUTCH CORALL STUDY GROUP (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2005.01499.x · Cited by 79
Self-citationHypercholesterolemia, lipid-lowering agents, and the risk for brain infarction
Amarenco, P. (2001) · Neurology · doi:10.1212/wnl.57.suppl_2.s35 · Cited by 79
The impact of statins on psychological wellbeing: a systematic review and meta-analysis
O'Neil, A., Sanna, L., Redlich, C., Sanderson, K., Jacka, F., Williams, L. J., Pasco, J. A., & Berk, M. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-154 · Cited by 78
Medication adherence trends with statins
Huser, M. A., Evans, T. S., & Berger, V. (2005) · Advances in Therapy · doi:10.1007/bf02849887 · Cited by 78
Transplacental transfer and distribution of pravastatin
Nanovskaya, T. N., Patrikeeva, S., Paúl, J., Costantine, M. M., Hankins, G. D. V., & Ahmed, M. S. (2013) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2013.05.038 · Cited by 78
Statins in community acquired pneumonia: Evidence from experimental and clinical studies
Chalmers, J. D., Short, P. M., Mandal, P., Akram, A. R., & Hill, A. T. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2010.04.005 · Cited by 78
Leurs, L. J., Visser, P., Laheij, R. J. F., Buth, J., Harris, P. L., & Blankensteijn, J. D. (2006) · Vascular · doi:10.2310/6670.2006.00010 · Cited by 78
Statins: an essential component in the management of carotid artery disease
Paraskevas, K. I., Hamilton, G., & Mikhailidis, D. P. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2007.03.035 · Cited by 77
Pleiotropic Effects of Statins: Evidence Against Benefits Beyond LDL-Cholesterol Lowering
Pedersen, T. R. (2010) · American Journal Cardiovascular Drugs · doi:10.2165/1158822-s0-000000000-00000 · Cited by 74
Metadata
- Authors
- The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1998-11-05
- Volume
- 339
- Issue
- 19
- Pages
- 1349-1357
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W38523360
- Cited by
- 5,261
- References
- 21
- Citations by year
- 2026: 19 · 2025: 24 · 2024: 57 · 2023: 53 · 2022: 60 · 2021: 58 · 2020: 72 · 2019: 82 · 2018: 81 · 2017: 94 · 2016: 114 · 2015: 111 · 2014: 118 · 2013: 167 · 2012: 147
- FWCI
- 312.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- pravastatin, coronary artery disease, statin therapy, cholesterol-lowering therapy, cardiovascular mortality, myocardial infarction, unstable angina, stroke, coronary revascularization, total cholesterol, secondary prevention, lipid-lowering diet
- MeSH terms
- Adult, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Female, Humans, Lipids, Male, Middle Aged, Mortality, Myocardial Infarction, Risk, Incidence, Pravastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
